A pilot trial of Prazosin, an alpha-1 adrenergic antagonist, for comorbid alcohol dependence and posttraumatic stress disorder

Alcoholism: Clinical and Experimental Research

Volumn 39, Issue 5, 2015, Pages 808-817

  Simpson, Tracy L ^a,b   Malte, Carol A ^a   Dietel, Bergetta ^a,c   Tell, Dana ^a,c   Pocock, Ian ^a,c   Lyons, Robert ^a,c   Varon, Dana ^a,c   Raskind, Murray ^a,b   Saxon, Andrew J ^a,b  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Seattle Institute for Biomedical and Clinical Research   (United States)

Author keywords

Alcohol dependence; Human clinical trial; Noradrenergic; Posttraumatic stress disorder; Prazosin

Indexed keywords

ANTIDEPRESSANT AGENT; ATENOLOL; CENTRAL STIMULANT AGENT; PLACEBO; PRAZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; BEDTIME DOSAGE; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG SAFETY; EVENING DOSAGE; FATIGUE; FEMALE; HEADACHE; HUMAN; INTERACTIVE VOICE RESPONSE SYSTEM; MALE; MORNING DOSAGE; NAUSEA; ORTHOSTATIC HYPOTENSION; OUTPATIENT; PILOT STUDY; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TELEPHONE; WEIGHT REDUCTION; WITHDRAWAL SYNDROME; COMPLICATION; CRAVING; DRUG EFFECTS; MIDDLE AGED; SLEEP STAGE; STRESS DISORDERS, POST-TRAUMATIC; TREATMENT OUTCOME; YOUNG ADULT;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ADULT; ALCOHOLISM; CRAVING; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PRAZOSIN; SLEEP STAGES; STRESS DISORDERS, POST-TRAUMATIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84927698343     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/acer.12703     Document Type: Article

References (49)

1. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders. 4th ed text rev. American Psychiatric Association, Washington, DC.
2. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A, COMBINE Study Research Group (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence: the combine study: a randomized controlled trial. JAMA 295: 2003-2017.
3. Bailey CR, Cordell E, Sobin SM, Neumeister A (2013) Recent progress in understanding the pathophysiology of post-traumatic stress disorder: implications for targeted pharmacological treatment. CNS Drugs 27:221-232.
4. Batki SL, Pennington DL, Lasher B, Neylan TC, Metzler T, Waldrop A, Delucchi K, Herbst E (2014) Topiramate treatment of alcohol use disorder in veterans with posttraumatic stress disorder: a randomized controlled pilot trial. Alcohol Clin Exp Res 38:2169-2177.
5. Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS, Keane TM (1995) The development of a clinician-administered PTSD scale. J Trauma Stress 8:75-90.
6. Blanco C, Xu Y, Brady K, Pérez-Fuentes G, Okuda M, Wang S (2013) Comorbidity of posttraumatic stress disorder with alcohol dependence among US adults: results from national epidemiological survey on alcohol and related conditions. Drug Alcohol Depend 132:630-638.
7. Brady KT, Sonne S, Anton RF, Randall CL, Back SE, Simpson K (2005) Sertraline in the treatment of co-occurring alcohol dependence and posttraumatic stress disorder. Alcohol Clin Exp Res 29:395-401.
8. Cukor J, Spitalnick J, Difede J, Rizzo A, Rothbaum BO (2009) Emerging treatments for PTSD. Clin Psychol Rev 29:715-726.
9. Drapkin ML, Yusko D, Yasinski C, Oslin D, Hembree EA, Foa EB (2011) Baseline functioning among individuals with posttraumatic stress disorder and alcohol dependence. J Subst Abuse Treat 41:186-192.
10. First MB, Spitzer RL, Gibbon M, Williams JBW (1995) Structured Clinical Interview for Axis I DSM-IV Disorders, Patient Edition (SCID-I/P). Biometrics Research Department, NY State Psychiatric Institute, New York.
11. Flannery BA, Volpicelli JR, Pettianati HM (1999) Psychometric properties of the Penn Alcohol Craving Scale. Alcohol Clin Exp Res 23:1289-1295.
12. Foa EB, Riggs DS, Dancu CV, Rothbaum BO (1993) Reliability and validity of a brief instrument for assessing post-traumatic stress disorder. J Trauma Stress 6:459-473.
13. Foa EB, Yusko DA, McLean CP, Suvak MK, Bux DA Jr, Oslin D, O'Brien CP, Imms P, Riggs DS, Volpicelli J (2013) Concurrent naltrexone and prolonged exposure therapy for patients with comorbid alcohol dependence and PTSD: a randomized clinical trial. JAMA 310:488-495.
14. Fox HC, Anderson GM, Tuit K, Hansen J, Kimmerling A, Siedlarz KM, Morgan PT, Sinha R (2012) Prazosin effects on stress- and cue-induced craving and stress response in alcohol-dependent individuals: preliminary findings. Alcohol Clin Exp Res 36:351-360.
15. Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, Loewy JW, Ehrich EW, Vivitrex Study Group (2005) Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 293: 1617-1625.
16. Germain A, Richardson R, Moul DE, Mammen O, Haas G, Forman SD, Rode N, Begley A, Nofzinger EA (2012) Placebo-controlled comparison of prazosin and cognitive-behavioral treatments for sleep disturbances in US military veterans. J Psychosom Res 72:89-96.
17. Hawley RJ, Major LF, Schulman EA, Lake CR (1981) CSF levels of norepinephrine during alcohol withdrawal. Arch Neurol 38:289-292.
18. IBM Corporation (2013) IBM SPSS Statistics for Windows. Version 22.0. IBM Corporation, Armonk, NY.
19. Jacobsen LK, Southwick SM, Kosten TR (2001) Substance use disorders in patients with posttraumatic stress disorder: a review of the literature. Am J Psychiatry 158:1184-1190.
20. Jaillon P (1980) Clinical pharmacokinetics of prazosin. Clin Pharmacokinet 5:365-376.
21. Kash TL (2012) The role of biogenic amine signaling in the bed nucleus of the stria terminals in alcohol abuse. Alcohol 46:303-308.
22. Koob GF (2009) Brain stress systems in the amygdala and addiction. Brain Res 1293:61-75.
23. Kovacs GL, Soroncz M, Tegyei I (2002) Plasma catecholamines in ethanol tolerance and withdrawal in mice. Eur J Pharmacol 448:151-156.
24. Lê AD, Funk D, Juzytsch W, Coen K, Navarre BM, Cifani C, Shaham Y (2011) Effect of prazosin and guanfacine on stress-induced reinstatement of alcohol and food seeking in rats. Psychopharmacology 218:89-99.
25. McCarthy E, Petrakis I (2010) Epidemiology and management of alcohol dependence in individuals with post-traumatic stress disorder. CNS Drugs 24:997-1007.
26. Miller WR, Del Boca FK (1994) Measurement of drinking behavior using the Form 90 family of instruments. J Stud Alcohol Suppl 12:112-118.
27. Mitrano DA, Schroeder JP, Smith Y, Cortright JJ, Bubula N, Vezina P, Weinshenker D (2012) Alpha-1 adrenergic receptors are localized on presynaptic elements in the nucleus accumbens and regulate mesolimbic dopamine transmission. Neuropsychopharmacology 37:2161-2172.
28. Norman SB, Myers US, Wilkins KC, Goldsmith AA, Hristova V, Huang Z, McCullough KC, Robinson SK (2012) Review of biological mechanisms and pharmacological treatments of comorbid PTSD and substance use disorder. Neuropharmacology 62:542-551.
29. Patkar AA, Gopalakrishnan R, Naik PC, Murray HW, Vergare MJ, Marsden CA (2003) Changes in plasma noradrenaline and serotonin levels and craving during alcohol withdrawal. Alcohol Alcohol 38:224-231.
30. Petrakis IL (2014) Pharmacotherapy for PTSD and substance abuse among veterans. Paper presented at the New Clinical Drug Evaluation Unit (NCDEU) 53rd Annual Meeting, Hollywood, FL, May 28-31.
31. Petrakis IL, Poling J, Levinson C, Nich C, Carroll K, Ralevski E, Rounsaville B (2006) Naltrexone and disulfiram in patients with alcohol dependence and comorbid post-traumatic stress disorder. Biol Psychiatry 60:777-783.
32. Petrakis IL, Ralevski E, Desai N, Trevisan L, Gueorguieva R, Rounsaville B, Krystal JH (2012) Noradrenergic vs serotonergic antidepressant with or without naltrexone for veterans with PTSD and comorbid alcohol dependence. Neuropsychopharmacology 37:996-1004.
33. Pietrzak RH, Gallezot JD, Ding YS, Henry S, Potenza MN, Southwick SM, Krystal JH, Carson RE, Neumeister A (2013) Association of posttraumatic stress disorder with reduced in vivo norepinephrine transporter availability in the locus coeruleus. JAMA Psychiatry 70:1199-1205.
34. Raskind MA, Peskind ER, Hoff DJ, Hart KL, Holmes HA, Warren D, Shofer J, O'Connell J, Taylor F, Gross C, Rohde K, McFall ME (2007) A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biol Psychiatry 61:928-934.
35. Raskind MA, Peterson K, Williams T, Hoff DJ, Hart K, Holmes H, Homas D, Hill J, Daniels C, Calohan J, Millard SP, Rohde K, O'Connell J, Pritzl D, Feiszli K, Petrie EC, Gross C, Mayer CL, Freed MC, Engel C, Peskind ER (2013) A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan. Am J Psychiatry 170:1003-1010.
36. Rasmussen DD, Alexander LL, Raskind MA, Froehlich JC (2009) The alpha 1-adrenergic receptor antagonist, prazosin, reduces alcohol drinking in alcohol-preferring (P) rats. Alcohol Clin Exp Res 33:264-272.
37. Ray L, Hutchison K (2007) Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response. Arch Gen Psychiatry 64:1069-1077.
38. Shad MU, Suris AM, North CS (2011) Novel combination strategy to optimize treatment for PTSD. Hum Psychopharmacol 26:4-11.
39. Simpson TL, Saxon AJ, Meredith CW, Malte CA, McBride B, Ferguson LC, Gross CA, Hart KL, Raskind M (2009) A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence. Alcohol Clin Exp Res 33:255-263.
40. Simpson TL, Stappenbeck CA, Luterek JA, Lehavot K, Kaysen DL (2014) Drinking motives moderate daily relationships between PTSD symptoms and alcohol use. J Abnorm Psychol 123:237-247.
41. Sofuoglu M, Rosenheck R, Petrakis I (2014) Pharmacological treatment of comorbid PTSD and substance use disorder: recent progress. Addict Behav 39:428-433.
42. Stappenbeck CA, Luterek JA, Kaysen D, Rosenthal CF, Gurrad B, Simpson TL (2015) A controlled examination of two coping skills for daily alcohol use and PTSD symptom severity among dually diagnosed individuals. Behav Res Ther 66:8-17.
43. StataCorp LP (2013) Stata Statistical Software. Release 13. StataCorp LP, College Station, TX.
44. Strawn JR, Geracioti TD Jr (2008) Noradrenergic dysfunction and the psychopharmacology of posttraumatic stress disorder. Depress Anxiety 25:260-271.
45. Taylor FB, Martin P, Thompson C, Williams J, Mellman TA, Gross C, Peskind ER, Raskind MA (2008) Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: a placebo-controlled study. Biol Psychiatry 63:629-632.
46. Ventura R, Cabib S, Alcaro A, Orsini C, Puglisi-Allegra S (2003) Norepinephrine in the prefrontal cortex is critical for amphetamine-induced reward and mesoaccumbens dopamine release. J Neurosci 23:1879-1885.
47. Ventura R, De Carolis D, Alcaro A, Puglisi-Allegra S (2006) Ethanol consumption and reward depend on norepinephrine in the prefrontal cortex. NeuroReport 17:1813-1817.
48. Weathers FW, Litz BT, Herman DS, Huska JA, Keane TM (1993) The PTSD Checklist (PCL): reliability, validity, and diagnostic utility. Paper presented at the 9th annual meeting of the International Society for Traumatic Stress Studies, San Antonio, TX, November.
49. Weinshenker D, Rust NC, Miller NS, Palmiter RD (2000) Ethanol-associated behaviors of mice lacking norepinephrine. J Neurosci 20:3157-3164.